Terra Pharm, a Pennsylvania-based medical marijuana cultivation and research organization, has officially opened its cultivation and processing facility in Pittsburgh and celebrated the ribbon cutting of its first dispensary in Uniontown.
Terra Pharm was granted a clinical registrant license by the Pennsylvania Department of Health in October 2024. Under this license, it's authorized to operate a cultivation facility, a processing facility, and up to six dispensaries statewide.
Terra Pharm’s second dispensary, located in White Oak, is expected to open within the next few weeks, followed by a third location in Lancaster in late April. A fourth dispensary is expected to open early this summer in Penn Hills.
“We are proud to open our first Terra Pharm dispensary in Uniontown, providing residents of southwestern Pennsylvania with affordable, convenient access to safe and effective medical marijuana therapies for qualifying health conditions,” said Eric Hauser, RPh, President and CEO of Terra Pharm. “Our mission is to empower patients through natural therapeutic solutions, promote responsible access, and support the growing body of scientific evidence validating medical marijuana as a legitimate form of medicine.”
Hauser brings extensive experience to Terra Pharm, having served as president of Carlisle-based Organic Remedies, another Pennsylvania medical marijuana company, since its founding in 2018. He also expressed enthusiasm about collaborating with his alma mater, Duquesne University, to expand scientific research into medical marijuana as a therapeutic regimen.
Duquesne University Nasuti College of Osteopathic Medicine Partnership
Duquesne University Nasuti College of Osteopathic Medicine was certified in May 2024 as an Academic Clinical Research Center and has partnered with clinical registrant Terra Pharm, Inc. Through this partnership, researchers plan to evaluate the effectiveness of cannabinoid-based products for decreasing the use of opioid pain medication among individuals with non-cancer chronic pain. Additional studies will focus on optimizing transdermal medical marijuana formulations for chronic pain treatment.
“While several universities are conducting research on the therapeutic benefits of medical marijuana, much more can be done to advance our understanding of its role as an alternative to traditional pain medications,” said Dr. John Kauffman, Dean, Nasuti College of Osteopathic Medicine. “We are proud to partner with Terra Pharm and look forward to launching studies that may significantly benefit patients with serious medical conditions.”
